0001759655-25-000093
SEC filingRevenue grew 23.4% to $521M, driven by FFS and capitated growth, but operating margin compressed to 0.6% on higher expenses.
Privia Health reported strong revenue growth of 23.4% year-over-year to $521.2 million in Q2 2025, driven primarily by a 20.2% increase in FFS-patient care revenue to $331.5 million and a 33.8% surge in capitated revenue to $75.5 million. The expansion reflects the addition of 621 new Implemented Providers (up 13.8% to 5,125) and a 15.2% increase in Attributed Lives to 1.38 million, aided by entry into Indiana and Arizona markets. However, gross profit margin declined to 21.6% from 23.3% as provider expenses grew 25.9% to $406.0 million, outpacing revenue growth. Operating income fell 34.6% to $3.3 million, yielding a razor-thin operating margin of 0.6% (down from 1.2%). Net income attributable to PRVA decreased 22.5% to $2.7 million, weighed by higher general and administrative expenses (up 29.8%) and stock-based compensation. Despite GAAP weakness, adjusted EBITDA rose 31.6% to $29.0 million, with margin expanding to 25.2% of Care Margin from 22.1%, highlighting underlying scalability.
Revenue mix shifted toward value-based care, with VBC revenue (capitated, shared savings, care management fees) increasing to 29.3% of total revenue from 26.6% a year ago. Capitated revenue benefited from a larger attributed population under at-risk contracts. Shared savings revenue jumped 50.7% to $60.0 million, partly due to timing of settlements. FFS-patient care remains the largest segment at 63.6% of revenue, growing 20.2% on higher visit volumes. Care management fees grew modestly by 4.7%. The Care Margin, a key non-GAAP metric, rose 15.4% to $115.2 million, but as a percentage of revenue it compressed to 22.1% from 23.6%, reflecting strategic investments in platform and personnel.
Management emphasized continued investments in growth, including sales and marketing, technology, and clinical capabilities to support VBC expansion. The company expects Care Margin to grow in absolute dollars as the provider base expands, and Platform Contribution and Adjusted EBITDA to benefit from operating leverage over time. No explicit quantitative guidance was provided, but the forward tone remains optimistic, citing organic momentum, new market entry, and a disciplined asset-light model. The increase in non-recurring expenses ($4.2 million in Q2 2025 vs. $0.7 million a year ago) was flagged as a temporary item, largely tied to severance and equity tax costs.
As of June 30, 2025, Privia Health held $390.1M in cash and cash equivalents, with total assets of $1.27B. The company has no outstanding debt under its $125M senior secured revolving credit facility, which expires in November 2028. Total stockholders' equity stood at $733.5M, including $50.7M non-controlling interest. Accounts receivable increased to $444.0M from $316.2M at year end, reflecting growth and the Arizona acquisition. Provider liability rose to $458.1M, driven by increased capitated arrangements.
Note 10 states there are no material commitments or contingencies as of June 30, 2025. The company has no operating lease obligations beyond those recognized on the balance sheet ($6.5M total lease liability). No material purchase commitments were disclosed.
Privia Health has no active share repurchase program or dividend policy. Capital allocation focused on the $89.1M acquisition of a 51% interest in Privia Medical Group Arizona, funded from existing cash. The company also incurred $36.6M in stock-based compensation (included in operating expenses), with $121.3M unrecognized comp cost expected over 1.0 year. No capital expenditures were separately disclosed in the notes; PPE net declined from $1.2M to $0.8M.
Note 13 states that the company operates as a single reporting segment. The CODM uses consolidated net income attributable to Privia Health Group, Inc. ($2.7M for Q2, $6.9M YTD) to allocate resources. While the company serves 16 markets, geographic financial data is not disclosed at the segment level.
Net income for H1 2025 was $9.3M, but operating cash flow was negative $16.1M, indicating significant working capital investment. The primary drivers were a $121.5M increase in accounts receivable and a $81.2M increase in provider liability, partially offset by stock-based compensation of $36.6M and depreciation/amortization of $4.5M. The negative operating cash flow suggests that revenue growth required substantial upfront cash outlays for receivables.
Capital expenditures (capex) are not explicitly disclosed; however, investing cash flow included $89.1M for business acquisitions and no separate capex line. Free cash flow cannot be reliably computed without capex figures. There were no share repurchases or dividends during the period.
Cash balance decreased by $101.0M to $390.1M at period end. The company's cash flow from operations is heavily influenced by working capital dynamics and acquisition activity, which may normalize over time.